Americas Sterility Testing Companies

Latest Americas Sterility Testing Companies Update

Mar 2023: For the intended Phase I clinical trial of EB-373 for treating anxiety disorders, Enveric Biosciences and Australian contract research organization (CRO) Avance Clinical have inked a deal. As per the agreement, Avance Clinical will oversee the trial in collaboration with Enveric Therapeutics, the recently founded Australian branch of Enveric Biosciences. The goal of the dose-escalating, multi-cohort clinical trial is to evaluate the care and tolerability of EB-373, the company's main candidate. It is anticipated to start in the fourth quarter of this year. Using Enveric Biosciences' Psybrary drug discovery platform, the next-generation psilocin prodrug EB-373 was created with anxiety disorders in mind. Preclinical research revealed that it interacted efficiently with many serotonin receptor types, such as the serotonin 5-HT2A receptor.

Nov 2023: The debut of CliniPrime Cryopreserved Leukopaks for cell therapy creation and production marks the extension of Charles River Laboratories International, Inc.'s GMP-compliant CliniPrimeTM line of products. Regulations about the creation of clinical trials and the commercial production of cutting-edge treatments are met by all CliniPrime products. As gene-modified cell treatments progress, there is an increasing demand for dependable and consistent supplies of donor-derived, GMP-compliant cellular starting material. Cryopreserved leukopaks are now popular among many cell therapy developers and essential to research and development. The best results for cellular viability, product uniformity, and long-term availability are obtained by cryopreservation soon after leukopak collection.

• Charles River Laboratories International, Inc. (US)


• Avance Biosciences (US)


• Boston Scientific Corporation (US)


• Paragon Bioservices, Inc (US)


• Thermo Fisher Scientific, Inc. (U.S.)


• Avista Pharma Solutions (US)


• DYNALABS LLC. (US)


• Merck KGaA (Germany)